Literature DB >> 24891880

Biological therapies for spondyloarthritis.

Vincenzo Bruner1, Mariangela Atteno1, Angelo Spanò1, Raffaele Scarpa1, Rosario Peluso2.   

Abstract

Biological therapies and new imaging techniques have changed the therapeutic and diagnostic approach to spondyloarthritis. In patients with axial spondyloarthritis, tumor necrosis factor α (TNFα) inhibitor treatment is currently the only effective therapy in patients for whom conventional therapy with nonsteroidal anti-inflammatory drugs (NSAIDs) has failed. TNFα inhibitor treatment is more effective in preventing articular damage in peripheral joints than in axial ones. It is important to treat patients at an early stage of disease to reduce disease progression; moreover it is necessary to identify causes of therapy inefficacy in preventing joint damage in the axial subset.

Entities:  

Keywords:  biological therapy; spondyloarthritis; tumor necrosis factor

Year:  2014        PMID: 24891880      PMCID: PMC4040940          DOI: 10.1177/1759720X14535512

Source DB:  PubMed          Journal:  Ther Adv Musculoskelet Dis        ISSN: 1759-720X            Impact factor:   5.346


  86 in total

1.  Lack of efficacy of abatacept in axial spondylarthropathies refractory to tumor-necrosis-factor inhibition.

Authors:  Fernando Kemta Lekpa; Valérie Farrenq; Florence Canouï-Poitrine; Muriel Paul; Xavier Chevalier; Rémy Bruckert; Sylvie Bastuji-Garin; Pascal Claudepierre
Journal:  Joint Bone Spine       Date:  2011-04-15       Impact factor: 4.929

2.  Sustained response to anakinra in ankylosing spondylitis.

Authors:  A N Bennett; A L Tan; L C Coates; P Emery; H Marzo-Ortega; D McGonagle
Journal:  Rheumatology (Oxford)       Date:  2007-12-11       Impact factor: 7.580

3.  Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers.

Authors:  Salvatore Iervolino; Matteo Nicola Dario Di Minno; Rosario Peluso; Mariana Lofrano; Anna Russolillo; Giovanni Di Minno; Raffaele Scarpa
Journal:  J Rheumatol       Date:  2012-01-15       Impact factor: 4.666

Review 4.  The diagnostic utility of MRI in spondyloarthritis.

Authors:  Susanne J Pedersen; Ulrich Weber; Mikkel Ostergaard
Journal:  Best Pract Res Clin Rheumatol       Date:  2012-12       Impact factor: 4.098

5.  Magnetic resonance imaging of nail unit in psoriatic arthritis.

Authors:  Ernesto Soscia; Raffaele Scarpa; Marco Amedeo Cimmino; Mariangela Atteno; Rosario Peluso; Cesare Sirignano; Luisa Costa; Salvatore Iervolino; Francesco Caso; Antonio Del Puente; Marco Salvatore; Andrea Soricelli
Journal:  J Rheumatol Suppl       Date:  2009-08

Review 6.  Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis - a five-year update.

Authors:  Denis Poddubnyy; Martin Rudwaleit
Journal:  Expert Opin Biol Ther       Date:  2013-09-27       Impact factor: 4.388

7.  Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-α blockers and traditional disease-modifying antirheumatic drugs.

Authors:  Matteo Nicola Dario Di Minno; Salvatore Iervolino; Rosario Peluso; Raffaele Scarpa; Giovanni Di Minno
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-01-06       Impact factor: 8.311

8.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

Review 9.  Certolizumab pegol in axial spondyloarthritis.

Authors:  In-Ho Song; Martin Rudwaleit
Journal:  Expert Rev Clin Immunol       Date:  2013-12       Impact factor: 4.473

Review 10.  Etanercept: a review of its use in the management of ankylosing spondylitis and psoriatic arthritis.

Authors:  Sheridan M Hoy; Lesley J Scott
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more
  7 in total

Review 1.  Safety Profile of Certolizumab Pegol in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis.

Authors:  Alice Capogrosso Sansone; Stefania Mantarro; Marco Tuccori; Elisa Ruggiero; Sabrina Montagnani; Irma Convertino; Alessandra Marino; Matteo Fornai; Luca Antonioli; Tiberio Corona; Danila Garibaldi; Corrado Blandizzi
Journal:  Drug Saf       Date:  2015-10       Impact factor: 5.606

Review 2.  Management of arthropathy in inflammatory bowel diseases.

Authors:  Rosario Peluso; Francesco Manguso; Maria Vitiello; Salvatore Iervolino; Matteo Nicola Dario Di Minno
Journal:  Ther Adv Chronic Dis       Date:  2015-03       Impact factor: 5.091

3.  Patient Concerns and Perceptions Regarding Biologic Therapies in Ankylosing Spondylitis: Insights From a Large-Scale Survey of Social Media Platforms.

Authors:  Eldin Dzubur; Carine Khalil; Christopher V Almario; Benjamin Noah; Deeba Minhas; Mariko Ishimori; Corey Arnold; Yujin Park; Jonathan Kay; Michael H Weisman; Brennan M R Spiegel
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-02       Impact factor: 4.794

Review 4.  Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies.

Authors:  Francesco Caso; Luisa Costa; Antonio Del Puente; Matteo Nicola Dario Di Minno; Gelsy Lupoli; Raffaele Scarpa; Rosario Peluso
Journal:  Ther Adv Chronic Dis       Date:  2015-11       Impact factor: 5.091

Review 5.  Medical Treatment of Ankylosing Spondylitis.

Authors:  Kyoung-Ho Moon; Young-Tae Kim
Journal:  Hip Pelvis       Date:  2014-09-29

Review 6.  Disease-Modifying Effects of Long-Term and Continuous Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Spondyloarthritis.

Authors:  Rebecca S Y Wong
Journal:  Adv Pharmacol Sci       Date:  2019-01-29

7.  Analysis of gene expression profiles and protein-protein interaction networks in multiple tissues of systemic sclerosis.

Authors:  Elham Karimizadeh; Ali Sharifi-Zarchi; Hassan Nikaein; Seyedehsaba Salehi; Bahar Salamatian; Naser Elmi; Farhad Gharibdoost; Mahdi Mahmoudi
Journal:  BMC Med Genomics       Date:  2019-12-27       Impact factor: 3.063

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.